Holen Sie sich die Stockscreener-App
161.86
1.18%
-1.94
Handel nachbörslich:
161.86
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$163.80
Offen:
$163.63
24-Stunden-Volumen:
1.40M
Relative Volume:
1.13
Marktkapitalisierung:
$18.64B
Einnahmen:
$9.54B
Nettoeinkommen (Verlust:
$841.00M
KGV:
21.76
EPS:
7.44
Netto-Cashflow:
$1.02B
1W Leistung:
-3.65%
1M Leistung:
-3.14%
6M Leistung:
+9.83%
1J Leistung:
+26.02%
1-Tages-Spanne:
$160.02
$164.03
1-Wochen-Bereich:
$160.02
$169.69
52-Wochen-Spanne:
$128.38
$178.87
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
161.86 | 18.64B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
421.85 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
184.96 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
406.65 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
100.26 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
141.22 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics Incorporated (DGX): A Bull Case Theory - Yahoo
Examining the Future: Quest Diagnostics's Earnings Outlook - Nasdaq
Drug Abuse Testing Market Forecast Report and Company - GlobeNewswire
Drug Abuse Testing Market Forecast Report and Company Analysis 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad Labs, Medtronic - Yahoo
Quest Diagnostics Declares Quarterly Cash Dividend - Quantisnow
Drug Screening Market Size Worth USD 10.34 Billion by 2034 | CAGR of 4.84% from 2025 to 2034 - GlobeNewswire Inc.
Peering Into Quest Diagnostics's Recent Short Interest - Benzinga
Price Over Earnings Overview: Quest Diagnostics - Benzinga
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings - MSN
Quest Diagnostics price target raised to $198 from $190 at BofA - Yahoo Finance
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Quest Diagnostics (DGX): Price Target Increased to $198 by BofA Analyst | DGX Stock News - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest introduces blood test to confirm amyloid brain pathology in Alzheimer’s - Medical Device Network
Quest Diagnostics (NYSE:DGX) Unveils New Alzheimer's Blood Test With Promising Predictive Accuracy - Yahoo Finance
Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease - PR Newswire
Revolutionary Blood Test Transforms Alzheimer's Diagnosis: Quest's New 91%-Accurate Solution - Stock Titan
Here's What to Expect From Quest Diagnostics’ Next Earnings Report - MSN
Quest Diagnostics : To Speak At The 38th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Compensation Up For Quest Diagnostics GC After Earlier Dip - Law360
Quest Diagnostics (DGX) Shares Cross 2% Yield Mark - Nasdaq
Here's What To Expect From Quest Diagnostics’ Next Earnings Report - Barchart.com
Lobbying Update: $80,000 of QUEST DIAGNOSTICS INCORPORATED lobbying was just disclosed - Nasdaq
Quest Diagnostics CEO sells $6.6 million in stock By Investing.com - Investing.com South Africa
Quest Diagnostics CEO sells $6.6 million in stock - Investing.com
Quest Diagnostics SVP Karthik sells $434,350 in stock By Investing.com - Investing.com Canada
Quest Diagnostics SVP Karthik sells $434,350 in stock - Investing.com
Quest Diagnostics' (NYSE:DGX) Dividend Will Be Increased To $0.80 - Yahoo Finance
Ex-Dividend Reminder: Quest Diagnostics, Preferred Bank and Erie Indemnity - Nasdaq
Redburn Atlantic Initiates Quest Diagnostics at Buy With $195 Price Target - MarketScreener
Quest Diagnostics Incorporated (NYSE:DGX) Passed Our Checks, And It's About To Pay A US$0.80 Dividend - Yahoo
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target - Quantisnow
Quest Revolutionizes Cervical Cancer Screening with New Self-Collection Test - Stock Titan
Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025 - Nasdaq
Quest Health Review 2025: Services, Pricing, and Reliability - Healthline
Quest Diagnostics Incorporated (NYSE:DGX) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Is Quest Diagnostics Stock Outperforming the S&P 500? - MSN
SVP for Diagnostic Services Plewman Patrick covered exercise/tax liability with 162 shares, decreasing direct ownership by 0.77% to 20,988 units (SEC Form 4) - Quantisnow
Is Quest Diagnostics Stock Worth Holding Onto Right Now? - MSN
Nephron Research Downgrades Quest Diagnostics to Hold From Buy, $184 Price Target - Marketscreener.com
Is Quest Diagnostics Stock Outperforming The S&P 500? - Barchart.com
Truist maintains hold on Quest Diagnostics stock, $182 target By Investing.com - Investing.com Australia
Quest Diagnostics (DGX) and Google Cloud to Transform Healthcare Data with AI - Insider Monkey
DGX Stock Set to Benefit From New Google Cloud Partnership - MSN
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):